How much funding has Eikon Therapeutics raised?

Eikon Therapeutics has raised $1.1B in total funding, most recently a Series D round.

Who are Eikon Therapeutics's investors?

Eikon Therapeutics's investors include T. Rowe Price, Andreessen Horowitz, Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group.

When was Eikon Therapeutics founded?

Eikon Therapeutics was founded in 2019.

Where is Eikon Therapeutics headquartered?

Eikon Therapeutics is headquartered in Hayward, California, United States.

What industry is Eikon Therapeutics in?

Eikon Therapeutics operates in Artificial Intelligence, Biotech, Drug Discovery, Healthcare.

How many employees does Eikon Therapeutics have?

Eikon Therapeutics has 201-500 employees.

Eikon Therapeutics

formerly EikonIPO

Bringing breakthrough therapeutics to patients with serious illnesses

Public · Hayward, United States · Founded 2019 · $1.1B raised

Artificial Intelligence

Biotech

Drug Discovery

Healthcare

Headquarters: Hayward, California
Employees: 201–500
Founded: 2019
Business Model: B2B
Website: eikontx.com

Total Funding: $1.1B
Last Round: $350.7M Series DFeb 2025
Rounds: 4
Type: Public

About

Eikon Therapeutics is a clinical-stage biopharmaceutical company that has built the world's first high-throughput single-molecule tracking (htSMT) platform, enabling visualization of hundreds of thousands of protein motion events in living cells in under a second. Founded on Nobel Prize-winning super-resolution microscopy by Eric Betzig, Eikon uses this platform to discover and develop breakthrough oncology and neurological therapeutics. The company completed an IPO in early 2026, raising $381 million.

Summary

Eikon Therapeutics is an Artificial Intelligence company based in Hayward, United States, founded in 2019. It has raised $1.1B in total across 4 rounds, most recently a $350.7M Series D round in Feb 2025. Investors include T. Rowe Price, Andreessen Horowitz and Lux Capital.

LinkedIn X (Twitter)